Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications

被引:889
作者
Kawabata, Yohei [1 ,2 ,3 ]
Wada, Koichi [3 ]
Nakatani, Manabu [3 ]
Yamada, Shizuo [1 ,2 ]
Onoue, Satomi [1 ,2 ]
机构
[1] Univ Shizuoka, Dept Pharmacokinet & Pharmacodynam, Suruga ku, Shizuoka 4228526, Japan
[2] Univ Shizuoka, Global Ctr Excellence COE Program, Sch Pharmaceut Sci, Suruga Ku, Shizuoka 4228526, Japan
[3] Nippon Boehringer Ingelheim Co Ltd, Dept Chem Mfg & Control, Kobe Pharma Res Inst, Chuo Ku, Kobe, Hyogo 6500047, Japan
关键词
Bioavailability; Biopharmaceutics classification system; Formulation development; Nanoparticle; Poorly water-soluble drugs; Solid dispersion; AMORPHOUS SOLID DISPERSION; MICROENVIRONMENTAL PH MODULATION; IMPROVE ORAL BIOAVAILABILITY; PARTICLE-SIZE REDUCTION; PHARMACEUTICAL APPLICATIONS; DELIVERY REVIEWS; IN-VITRO; ENHANCED BIOAVAILABILITY; DISSOLUTION RATE; VIVO EVALUATION;
D O I
10.1016/j.ijpharm.2011.08.032
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The poor oral bioavailability arising from poor aqueous solubility should make drug research and development more difficult. Various approaches have been developed with a focus on enhancement of the solubility, dissolution rate, and oral bioavailability of poorly water-soluble drugs. To complete development works within a limited amount of time, the establishment of a suitable formulation strategy should be a key consideration for the pharmaceutical development of poorly water-soluble drugs. In this article, viable formulation options are reviewed on the basis of the biopharmaceutics classification system of drug substances. The article describes the basic approaches for poorly water-soluble drugs, such as crystal modification, micronization, amorphization, self-emulsification, cyclodextrin complexation, and pH modification. Literature-based examples of the formulation options for poorly water-soluble compounds and their practical application to marketed products are also provided. Classification of drug candidates based on their biopharmaceutical properties can provide an indication of the difficulty of drug development works. A better understanding of the physicochemical and biopharmaceutical properties of drug substances and the limitations of each delivery option should lead to efficient formulation development for poorly water-soluble drugs. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 104 条
  • [51] Enhanced Bioavailability of Probucol Following the Administration of Solid Dispersion Systems of Probucol-Polyvinylpyrrolidone in Rabbits
    Kubo, Yoshitada
    Tfrashima, Yuuji
    Yagi, Naomi
    Nochi, Hiromi
    Tamoto, Koichi
    Sekikawa, Hitoshi
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2009, 32 (11) : 1880 - 1884
  • [52] Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion
    Kushida, I
    Ichikawa, M
    Asakawa, N
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (01) : 258 - 266
  • [53] Application of Melt Extrusion in the Development of a Physically and Chemically Stable High-Energy Amorphous Solid Dispersion of a Poorly Water-Soluble Drug
    Lalkshman, Jay P.
    Cao, Yu
    Kowalski, James
    Serajuddin, Abu T. M.
    [J]. MOLECULAR PHARMACEUTICS, 2008, 5 (06) : 994 - 1002
  • [54] Ritonavir-PEG 8000 amorphous solid dispersions:: In vitro and in vivo evaluations
    Law, D
    Schmitt, EA
    Marsh, KC
    Everitt, EA
    Wang, WL
    Fort, JJ
    Krill, SL
    Qiu, YH
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (03) : 563 - 570
  • [55] Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH
    Li, SF
    Wong, SM
    Sethia, S
    Almoazen, H
    Joshi, YM
    Serajuddin, ATM
    [J]. PHARMACEUTICAL RESEARCH, 2005, 22 (04) : 628 - 635
  • [56] Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings (Reprinted from Advanced Drug Delivery Reviews, vol 23, pg 3-25, 1997)
    Lipinski, CA
    Lombardo, F
    Dominy, BW
    Feeney, PJ
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) : 3 - 26
  • [57] Drug-like properties and the causes of poor solubility and poor permeability
    Lipinski, CA
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 44 (01) : 235 - 249
  • [58] Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate
    Liu, C
    Wu, JH
    Shi, B
    Zhang, YX
    Gao, TK
    Pei, YY
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2006, 32 (01) : 115 - 123
  • [59] PARTICLE-SIZE REDUCTION FOR IMPROVEMENT OF ORAL BIOAVAILABILITY OF HYDROPHOBIC DRUGS .1. ABSOLUTE ORAL BIOAVAILABILITY OF NANOCRYSTALLINE DANAZOL IN BEAGLE DOGS
    LIVERSIDGE, GG
    CUNDY, KC
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 125 (01) : 91 - 97
  • [60] Modern bioavailability, bioequivalence and biopharmaceutics classification system.: New scientific approaches to international regulatory standards
    Löbenberg, R
    Amidon, GL
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) : 3 - 12